Investigators are using checkpoint inhibitors (CPIs) to treat aggressive hematologic
malignancies in patients undergoing allogeneic hematopoietic stem cell transplantation (allo …

Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative
therapy for high-risk hematological malignancies, but the development of severe and/or …

Administration of posttransplant cyclophosphamide (PTCy) has significantly expanded the
number of patients undergoing HLA-haploidentical hematopoietic cell transplantation (haplo …

Anti-PD-1 monoclonal antibodies yield high response rates in patients with
relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually …

Calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis is standard in
allogeneic hematopoietic stem cell transplantation (HCT) but fails to induce long-term …

The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has
evolved significantly over the past decade after the approval of brentuximab vedotin (BV) …

Autologous stem cell transplantation (ASCT) can be curative for patients with
relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 …

Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit
from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched …

Anti-PD-1 monotherapy had limited clinical efficacy in relapsed/refractory (r/r) AML patients
with higher PD-1 and PD-L1 expression. Hence, we investigated the efficacy and safety of …

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has
improved considerably in recent years owing to the approval of highly active novel agents …